The Stamford Hospital
- Type
- Teaching hospital
- Where
- Stamford, CT
- Medicare CCN
- 070006
- Received
- $192,860 in 113 records, 2020 ($23,735 general, $169,124 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STAMFORD HOSPITAL Fuzzy (name and state)
- Plan sponsor: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Nonprofit: STAMFORD HOSPITAL Fuzzy (name and state)
- Trademark owner: The Stamford Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 55 | $23,735 |
| 2020 | Research payment | 58 | $169,124 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Genentech, Inc. | 9 | $38,823 | 2020 |
| E.R. Squibb & Sons, L.L.C. | 2 | $19,459 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $18,717 | 2020 |
| Amgen Inc. | 5 | $15,620 | 2020 |
| AstraZeneca Pharmaceuticals LP | 1 | $14,608 | 2020 |
| F. Hoffmann-La Roche AG | 1 | $11,703 | 2020 |
| Janssen Research & Development, LLC | 1 | $10,046 | 2020 |
| EMD Serono, Inc. | 4 | $9,375 | 2020 |
| AKEBIA THERAPEUTICS INC | 8 | $9,146 | 2020 |
| Aesculap, Inc. | 8 | $9,045 | 2020 |
| KARL STORZ Endoscopy-America | 18 | $8,090 | 2020 |
| Incyte Corporation | 2 | $5,941 | 2020 |
| CSL Behring | 10 | $4,979 | 2020 |
| HOLOGIC INC | 1 | $3,800 | 2020 |
| Abbott Laboratories | 1 | $3,402 | 2020 |
| Tandem Diabetes Care, Inc. | 10 | $2,650 | 2020 |
| Celgene Corporation | 1 | $2,500 | 2020 |
| Stryker Corporation | 16 | $2,161 | 2020 |
| Boston Scientific Corporation | 4 | $1,001 | 2020 |
| Olympus America Inc. | 1 | $611 | 2020 |
| Regeneron Pharmaceuticals, Inc. | 1 | $600 | 2020 |
| GE HEALTHCARE | 1 | $577 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 58 | $169,124 |
| Gift | 27 | $17,747 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 26 | $4,811 |
| Charitable Contribution | 2 | $1,177 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-25 | Amgen Inc. | $1,675 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-12-17 | CSL Behring | $82 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-16 | Celgene Corporation | $2,500 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-12-10 | Aesculap, Inc. | $2,732 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,649 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,342 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,340 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,019 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $638 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $298 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $24 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-11-23 | Genentech, Inc. | $10,340 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2020 |
| 2020-11-18 | Janssen Research & Development, LLC | $10,046 | Research payment | Cash or cash equivalent | A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for | 2020 | |
| 2020-11-18 | Genentech, Inc. | $921 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2020 |
| 2020-11-16 | Boston Scientific Corporation | $224 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-11-03 | Olympus America Inc. | $611 | Gift | In-kind items and services | ThunderBeat Capital Device, Energy | 2020 | |
| 2020-10-30 | Bayer Healthcare Pharmaceuticals Inc. | $3,262 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-10-30 | Bayer Healthcare Pharmaceuticals Inc. | $3,262 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-23 | Genentech, Inc. | $6,267 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2020 |
| 2020-10-21 | Genentech, Inc. | $1,244 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2020 |
| 2020-10-14 | Genentech, Inc. | $1,244 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2020 |
| 2020-10-13 | Stryker Corporation | $414 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $187 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $86 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $23 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-07 | Genentech, Inc. | $4,485 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2020 |
| 2020-10-02 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-09-24 | CSL Behring | $92 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-08 | Boston Scientific Corporation | $224 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-08-21 | Bayer Healthcare Pharmaceuticals Inc. | $3,500 | Research payment | Cash or cash equivalent | Non-Covered | Bay1002670 Endometriosis Dose finding EU & US JP CN | 2020 |
| 2020-08-21 | Bayer Healthcare Pharmaceuticals Inc. | $1,375 | Research payment | Cash or cash equivalent | Non-Covered | Bay1002670 Endometriosis Dose finding EU & US JP CN | 2020 |
| 2020-08-21 | Amgen Inc. | $925 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-08-21 | Bayer Healthcare Pharmaceuticals Inc. | $550 | Research payment | Cash or cash equivalent | Non-Covered | Bay1002670 Endometriosis Dose finding EU & US JP CN | 2020 |
| 2020-07-30 | CSL Behring | $825 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-30 | CSL Behring | $675 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-30 | CSL Behring | $225 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-28 | E.R. Squibb & Sons, L.L.C. | $19,199 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemother | 2020 |
| 2020-07-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-06 | Stryker Corporation | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $85 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $8 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $6 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-02 | AKEBIA THERAPEUTICS INC | $4,704 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-07-01 | Genentech, Inc. | $3,977 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2020 |
| 2020-06-25 | CSL Behring | $131 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-06-20 | Amgen Inc. | $1,548 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-06-18 | AKEBIA THERAPEUTICS INC | $103 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-06-11 | E.R. Squibb & Sons, L.L.C. | $260 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospectiv | 2020 |
| 2020-05-19 | Amgen Inc. | $1,548 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-05-18 | Bayer Healthcare Pharmaceuticals Inc. | $4,268 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-05-14 | Regeneron Pharmaceuticals, Inc. | $600 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-05-14 | AKEBIA THERAPEUTICS INC | $217 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-05-01 | Stryker Corporation | $355 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $116 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $21 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $12 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-04-27 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-04-27 | CSL Behring | $498 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-22 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-04-09 | AKEBIA THERAPEUTICS INC | $834 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-04-09 | AKEBIA THERAPEUTICS INC | $171 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE C | 2020 | |
| 2020-04-08 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-04-08 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-04-06 | Boston Scientific Corporation | $493 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-03-09 | HOLOGIC INC | $3,800 | Research payment | Cash or cash equivalent | Paddle Device, Breast and Skeletal Health | Case Collection | 2020 |
| 2020-03-06 | Genentech, Inc. | $9,421 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2020 |
| 2020-03-03 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-03-02 | Genentech, Inc. | $921 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2020 |
| 2020-02-25 | AKEBIA THERAPEUTICS INC | $223 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-02-21 | Amgen Inc. | $9,924 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $60 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-02-10 | EMD Serono, Inc. | $5,750 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi) | 2020 |
| 2020-02-10 | EMD Serono, Inc. | $2,850 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi) | 2020 |
| 2020-02-10 | EMD Serono, Inc. | $550 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi) | 2020 |
| 2020-02-10 | EMD Serono, Inc. | $225 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi) | 2020 |
| 2020-02-05 | AstraZeneca Pharmaceuticals LP | $14,608 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2020 |
| 2020-02-04 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-04 | CSL Behring | $225 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-04 | CSL Behring | $225 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-03 | AKEBIA THERAPEUTICS INC | $742 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-01-31 | GE HEALTHCARE | $577 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-01-22 | Incyte Corporation | $5,845 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-01-15 | Abbott Laboratories | $3,402 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2020 |
| 2020-01-14 | Stryker Corporation | $418 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $152 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $43 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $15 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-13 | KARL STORZ Endoscopy-America | $1,050 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $736 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $716 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $696 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $683 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $527 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $465 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $447 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $439 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $436 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $371 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $322 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $281 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $268 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $214 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $200 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $138 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $91 | Gift | In-kind items and services | 2020 | ||
| 2020-01-02 | F. Hoffmann-La Roche AG | $11,703 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2020 |
| 2020-01-02 | AKEBIA THERAPEUTICS INC | $2,149 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) Stamford, CT | County Western Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 137,144 | 627,071 | 3,624,508 |
| Population, 2020 census P1 | 135,470 | - | 3,605,944 |
| Median age B01002 | 38.4 | 41.5 | 41.1 |
| Under 18 B01001 | 18.4% | 21.8% | 20.2% |
| 65 and over B01001 | 16.2% | 17.4% | 18.5% |
| Households B11001 | 55,291 | 235,379 | 1,434,007 |
| Foreign born B05002 | 31.3% | 23.8% | 15.7% |
| Median household income B19013 | $111,586 | $128,188 | $95,781 |
| Median family income B19113 | $126,493 | $161,625 | $122,706 |
| Per capita income B19301 | $67,068 | $82,266 | $55,915 |
| Poverty rate B17001 | 10.1% | 7.5% | 10.0% |
| Unemployment rate B23025 | 4.9% | 5.3% | 5.6% |
| Civilian labor force B23025 | 81,944 | 346,557 | 1,959,490 |
| Mean commute (minutes) B08013 | 28.5 | 30.8 | 26.5 |
| Bachelor's degree or higher B15003 | 51.7% | 55.5% | 42.5% |
| Housing units B25001 | 58,655 | 251,530 | 1,541,822 |
| Owner-occupied B25003 | 48.8% | 66.4% | 66.5% |
| Renters B25003 | 51.2% | 33.6% | 33.5% |
| Median home value B25077 | $624,400 | $652,900 | $366,900 |
| Median gross rent B25064 | $2,276 | $2,110 | $1,488 |
| White, not Hispanic B03002 | 43.2% | 58.6% | 61.9% |
| Black B03002 | 17.7% | 9.3% | 9.8% |
| Hispanic or Latino B03002 | 28.3% | 20.5% | 18.3% |
| Asian B03002 | 7.3% | 5.4% | 4.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.
Comments